AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Statistics

Total Valuation

AmCad BioMed has a market cap or net worth of TWD 791.66 million. The enterprise value is 510.59 million.

Market Cap	791.66M
Enterprise Value	510.59M

Important Dates

The next estimated earnings date is Friday, May 8, 2026.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 9.75% in one year.

Current Share Class	63.33M
Shares Outstanding	63.33M
Shares Change (YoY)	+9.75%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.64%
Owned by Institutions (%)	0.95%
Float	31.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.01
PB Ratio	1.32
P/TBV Ratio	1.72
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-9.16
EV / Sales	16.78
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.76

Financial Position

The company has a current ratio of 22.62, with a Debt / Equity ratio of 0.01.

Current Ratio	22.62
Quick Ratio	20.66
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-999.49

Financial Efficiency

Return on equity (ROE) is -11.29% and return on invested capital (ROIC) is -8.59%.

Return on Equity (ROE)	-11.29%
Return on Assets (ROA)	-8.34%
Return on Invested Capital (ROIC)	-8.59%
Return on Capital Employed (ROCE)	-14.55%
Weighted Average Cost of Capital (WACC)	6.12%
Revenue Per Employee	895,206
Profits Per Employee	-1.64M
Employee Count	34
Asset Turnover	0.05
Inventory Turnover	0.71

Taxes

Income Tax	-15,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.77% in the last 52 weeks. The beta is 0.34, so AmCad BioMed's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	-28.77%
50-Day Moving Average	13.78
200-Day Moving Average	15.13
Relative Strength Index (RSI)	26.40
Average Volume (20 Days)	41,892

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AmCad BioMed had revenue of TWD 30.44 million and -55.72 million in losses. Loss per share was -0.88.

Revenue	30.44M
Gross Profit	10.02M
Operating Income	-87.96M
Pretax Income	-71.40M
Net Income	-55.72M
EBITDA	-77.48M
EBIT	-87.96M
Loss Per Share	-0.88

Balance Sheet

The company has 365.22 million in cash and 4.75 million in debt, with a net cash position of 360.47 million or 5.69 per share.

Cash & Cash Equivalents	365.22M
Total Debt	4.75M
Net Cash	360.47M
Net Cash Per Share	5.69
Equity (Book Value)	600.82M
Book Value Per Share	8.23
Working Capital	391.87M

Cash Flow

In the last 12 months, operating cash flow was -47.06 million and capital expenditures -373,000, giving a free cash flow of -47.44 million.

Operating Cash Flow	-47.06M
Capital Expenditures	-373,000
Depreciation & Amortization	10.47M
Net Borrowing	-5.05M
Free Cash Flow	-47.44M
FCF Per Share	-0.75

Margins

Gross margin is 32.93%, with operating and profit margins of -288.97% and -183.06%.

Gross Margin	32.93%
Operating Margin	-288.97%
Pretax Margin	-234.59%
Profit Margin	-183.06%
EBITDA Margin	-254.57%
EBIT Margin	-288.97%
FCF Margin	n/a

Dividends & Yields

AmCad BioMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.75%
Shareholder Yield	-9.75%
Earnings Yield	-7.04%
FCF Yield	-5.99%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AmCad BioMed has an Altman Z-Score of 28.26 and a Piotroski F-Score of 2.

Altman Z-Score	28.26
Piotroski F-Score	2